Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the thirteen brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $8.30.
Several research firms have recently weighed in on ALLO. Weiss Ratings cut shares of Allogene Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 12th. Citizens Jmp restated a “market outperform” rating and issued a $6.00 target price on shares of Allogene Therapeutics in a research note on Monday.
Read Our Latest Report on ALLO
Allogene Therapeutics Stock Down 5.8%
Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.04. The firm had revenue of $4.64 million during the quarter, compared to the consensus estimate of $0.00 million. As a group, equities analysts expect that Allogene Therapeutics will post -0.59 EPS for the current year.
Institutional Investors Weigh In On Allogene Therapeutics
A number of institutional investors have recently made changes to their positions in the business. GTS Securities LLC bought a new stake in Allogene Therapeutics in the second quarter worth $27,000. Coastal Bridge Advisors LLC purchased a new position in shares of Allogene Therapeutics in the second quarter worth about $45,000. Public Employees Retirement System of Ohio bought a new stake in shares of Allogene Therapeutics in the 2nd quarter valued at about $554,000. Corient Private Wealth LP bought a new stake in shares of Allogene Therapeutics in the 2nd quarter valued at about $85,000. Finally, Bank of America Corp DE purchased a new stake in Allogene Therapeutics during the 2nd quarter valued at about $6,630,000. Hedge funds and other institutional investors own 83.63% of the company’s stock.
Allogene Therapeutics Company Profile
Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.
The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.
Featured Stories
- Five stocks we like better than Allogene Therapeutics
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
